Immunic (Immunic) Momentum Rank : 7 (As of May. 01, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Immunic Momentum Rank?

Immunic has the Momentum Rank of 7.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Immunic's Momentum Rank

For the Biotechnology subindustry, Immunic's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunic's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Immunic's Momentum Rank falls into.

Immunic Momentum Rank Related Terms

Thank you for viewing the detailed overview of Immunic's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunic (Immunic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (NAS:IMUX) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

10VA:Germany

Address

1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036

Website

https://www.imux.com

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Executives

Glenn Whaley	officer: PAO and Controller	C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Richard Alan Rudick	director	1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK NY 10036
Joerg Neermann	director	IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Daniel Vitt	director, officer: CEO, President	IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Monika Maria Toernsen	director	ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Duane Nash	director	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andreas Muehler	officer: Chief Medical Officer	1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK CITY NY 10036
Manfred Groeppel	officer: Chief Operating Officer	IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Barclay A Phillips	director	C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Tamar D Howson	director
Sanjay S Patel	officer: Chief Financial Officer	10 N. PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Claudio Nessi	10 percent owner	C/O NEOMED, 7 PLACE DU MOLARD, 1204 GENEVA V8 1204
Anne-mari Paster	10 percent owner	C/O OMEGA FUND MANAGEMENT, LLC, 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Lsp V Cooperatieve U.a.	10 percent owner	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV